Table 2.

Longitudinal Analysis of Change in Trajectories of Nucleocapsid Antigen, Anti-Nucleocapsid Antibody, C-Reactive Protein, Interleukin-6, and D-Dimer Associated With Neutralizing Monoclonal Antibody Treatment for Total Cohort and Trials of Individual Agents

		Plasma N-Ag (n = 2147)		Anti-N-Ab (n = 2149)		C-Reactive Protein (n = 1985)		Interleukin-6 (n = 2102)		D-Dimer (n = 2102)
	No.	GM Ratio (95% CI)	P a	Mean Difference (95% CI)	P a	GM Ratio (95% CI)	P a	GM Ratio (95% CI)	P a	GM Ratio (95% CI)	P a
Combined cohort	2149	0.80 (.73–.88)	<.001	−0.02 (−.11 to .07)	.412	0.96 (.89–1.03)	.470	1.03 (.93–1.13)	.011	1.03 (.99–1.08)	.979
Bamlanivimab	306	0.91 (.70–1.18)	.705	−0.17 (−.43 to .09)	.363	1.13 (.90–1.43)	.265	1.09 (.89–1.33)	.605	1.00 (.90–1.12)	.707
Sotrovimab	204	0.76 (.57–1.01)	.012	−0.05 (−.25 to .16)	.418	0.93 (.77–1.12)	.042	0.93 (.76–1.13)	.015	1.06 (.97–1.16)	.425
Amubarvimab-romlusevimab	250	0.69 (.53–.90)	<.001	0.12 (−.09 to .33)	.149	1.01 (.85–1.20)	.740	1.01 (.82–1.24)	.779	1.10 (1.01–1.20)	.661
Tixagevimab-cilgavimab	1339	0.81 (.72–.90)	<.001	−0.01 (−.12 to .09)	.412	0.93 (.85–1.02)	.470	1.03 (.91–1.17)	.011	1.04 (.99–1.10)	.979

Abbreviations: Ab, antibody; Anti-N-Ab, anti-nucleocapsid Ab as signal to cutoff ratio; CI, confidence interval; GM, geometric mean; n, number of participants with an available measurement at baseline and at least 1 follow-up sample; N-Ag, nucleocapsid antigen.

^a P value for heterogeneity of the treatment effect over time (interaction between treatment group and time; 3 categories: days 1, 3, and 5).